resolves between titrations Week 58 (retatrutide ~1 mg/week) Steady weight-loss rate (community-reported 12 lb/week) "Food noise" reduction strongest at this dose GI side effects easing as the body adapts to the stable dose Week 912 (retatrutide ~2 mg/week, maintenance entry point) Stable weight-loss curve Rate of loss consistent with retatrutide Phase 2 trajectory This is the reported entry point for adding cagrilintide By month 3, community-reported total weight loss on retatrutide alone clusters around 610%
To check if your insurance plan covers Wegovy, refer to your plans drug formulary, which includes a list of all the medications covered by your plan
Unlike injectable formulations that typically require cold-chain storage, oral GLP-1RAs bypass refrigeration constraints, thereby reducing manufacturing and distribution costs and improving accessibility in resource-limited settings [73]
Thus, reductions in energy intake with GLP-1Rbased pharmacotherapies reflect not only diminished appetite but may also involve a concomitant shift in food preference toward less energy-dense foods
At Midi, we prescribe personalized GLP-1 prescriptions for weight loss